Cited by 30Breast Cancer Treatment StudiesStatistical Methods in Clinical TrialsPancreatic and Hepatic Oncology Research

Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery

Open access
Marron, Thomas U., Galsky, Matthew D., Taouli, Bachir, Fiel, Maria Isabel, Ward, Stephen, Kim, Edward, Yankelevitz, David, Doroshow, Deborah +18 more·2022·Nature Medicine

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-022-01681-x

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The three initial HCC neoadjuvant studies demonstrate the utility of the window-of-opportunity setting and provide mechanistic insight because resected tumour tissue allows in-depth immune analysis instead of relying on scant on-treatment biopsies.

    “These three initial studies highlight the utility of the neoadjuvant ‘window-of-opportunity’ setting and provide insight on the mechanisms of action of ICIs, given the potential to use resected tumour tissue for in-depth immune analysis rather than relying on scant on-treatment biopsy samples128.”

    From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [128]

    Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [16]Lin J-R eLife 7, e31657 (2018).29993362

Cited by

Sorted by citations

Authors
Marron, T. U., Galsky, M. D., Taouli, B., Fiel, M. I., Ward, S., Kim, E., Yankelevitz, D., Doroshow, D., Guttman-Yassky, E., Ungar, B., Mehandru, S., Golas, B. J., Labow, D., Sfakianos, J., Nair, S. S., Chakravarty, D., Buckstein, M., Song, X., Kenigsberg, E., Gnjatic, S., Brown, B. D., Sparano, J., Tewari, A., Schwartz, M., Bhardwaj, N., & Merad, M.
Affiliations
  • Tisch Cancer Institute (US)
  • Icahn School of Medicine at Mount Sinai (US)
Corresponding author
Marron, Thomas U.
Venue
Nature Medicine
Published
2022-03-28
Volume
28
Issue
4
Pages
626-629
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4220731098
Cited by
30
References
25
Citations by year
2026: 6 · 2025: 4 · 2024: 8 · 2023: 10 · 2022: 2
FWCI
2.53
Type
journal article
Language
en
Open access
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (R01CA254104)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Keywords
neoadjuvant therapy, window-of-opportunity trial, anticancer drug discovery, mechanism of action, trial design, sample collection, sample analysis
MeSH terms
Antineoplastic Agents, Breast Neoplasms, Clinical Trials as Topic, Female, Humans, Neoplasms, Neoadjuvant Therapy, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review